Neuracle Science Technology
NS101h & NS150h
| Pipeline | NS101h&NS150h |
|---|---|
| Summary | NS101 is the first-in-class clinical-stage antibody drug targeting FAM19A5. Throughout the development of NS101, we have identified the potential for NS101 to be applied to a variety of indications. In addition, we are also developing various forms of backup antibodies, due to the needs for optimization of the half-life and efficacy of the antibody based on indication-specific characteristics, for increasing user-friendliness and affordability, and for risk management options to fall back on in the case of any issues with the lead antibody. |
